Emerging innovative therapeutic approaches targeting PCSK9 to lower lipids

Clinical Pharmacology and Therapeutics

Volumn 99, Issue 1, 2016, Pages 69-71

  Shantha, G P S ^a   Robinson, J G ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; ANTISENSE OLIGONUCLEOTIDE; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PEGDINETANIB; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

ADIPOSE TISSUE; APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DRUG TARGETING; GENE MUTATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; MOLECULAR MECHANICS; MONOTHERAPY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SECONDARY PREVENTION; TISSUE METABOLISM; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; ECONOMICS; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; HUMANS; HYPOLIPIDEMIC AGENTS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84955286686     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.281     Document Type: Article

References (100)

1. Navar-Boggan, A.M., et al,. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 131, 451-458 (2015).
2. Go, A.S., et al,. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129, 399-410 (2014).
3. The European health report 2012: charting the way to well-being (World Health Organization Regional Office for Europe, Copenhagen, 2012).
4. Windhaus, A., Uber den gehalt normaler and atheromatoser aorten an cholesterin und cholesterinester. Z. Physiol. Chem. 67, 174-176 (1910).
5. Verschuren, W.M., et al,. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. JAMA 274, 131-136 (1995).
6. Kassner, U., Schlabs, T., Rosada, A., &, Steinhagen-Thiessen, E., Lipoprotein(a)-an independent causal risk factor for cardiovascular disease and current therapeutic options. Atheroscler. Suppl. 18, 263-267 (2015).
7. Navar-Boggan, A.M., et al,. Hyperlipidemia in early adulthood increases long-term risk of coronary heart disease. Circulation 3, 131, 451-458 (2015).
8. Jonathan, A.T., Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat. Rev. Drug. Dis. 2, 517-526 (2003).
9. Sheng, X., Murphy, M.J., MacDonald, T.M., &, Wei, L., Effect of statins on total cholesterol concentrations and cardiovascular outcomes in patients with diabetes mellitus: a population-based cohort study. Eur. J. Clin. Pharmacol. 68, 1201-1208 (2012).
10. Aboa-Eboulé, C., et al,. Effect of previous statin therapy on severity and outcome in ischemic stroke patients: a population-based study. J. Neurol. 260, 30-37 (2013).
11. Baigent, C., et al,. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
12. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371, 117-125 (2008).
13. Baigent, C., et al,. SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377, 2181-2192 (2011).
14. Cholesterol Treatment Trialists' (CTT) Collaborators, Mihaylova, B., et al,. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 380, 581-590 (2011).
15. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher, J., et al,. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 385, 1397-1405 (2015).
16. Zhang, H., et al,. Discontinuation of statins in routine care settings: a cohort study. Ann. Intern. Med. 158, 526-534 (2013).
17. Pearson, T.A., Laurora, I., Chu, H., &, Kafonek, S., The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160, 459-467 (2000).
18. Sueta, C.A., et al,. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am. J. Cardiol. 83, 1303-1307 (1997).
19. Gitt, A.K., et al,. DYSIS Investigators. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada. Eur. J. Prev. Cardiol. 19, 221-230 (2012).
20. Avis, H.J., et al,. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J. Am. Coll. Cardiol. 55, 1121-1126 (2010).
21. Robinson, J.G., &, Goldberg, A.C., Treatment of adults with familial hypercholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S18-S29 (2011).
22. Stone, N.J., et al,. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 63, 2889-2934 (2014).
23. Paixao, A.R., Ayers, C.R., Berry, J.D., de Lemos, J.A., &, Khera, A., Atherosclerotic cardiovascular disease prevention: a comparison between the third adult treatment panel and the new 2013 Treatment of Blood Cholesterol Guidelines. Circ. Cardiovasc. Qual. Outcomes. 7, 778-779 (2014).
24. Yeboah, J., et al,. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA). Am. Heart J. 169, 387-395 (2015).
25. Pencina, M.J., et al,. Application of new cholesterol guidelines to a population-based sample. N. Engl. J. Med. 370, 1422-1431 (2014).
26. Robinson, J.G., Starting primary prevention earlier with statins. Am. J. Cardiol. 114, 1437-1442 (2014).
27. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care 38, S49-S57 (2014).
28. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (Clinical guideline 181). < www.nice.org.uk/guidance/CG181 > (2014).
29. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage, J., et al,. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376, 1658-1669 (2010).
30. Cholesterol Treatment Trialists' (CTT) Collaboration, Baigent, C., et al,. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376, 1670-1681 (2010).
31. The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropriprant in high-risk patients. N. Engl. J. Med. 371, 2003-2012 (2014).
32. The AIM-HIGH Investigators. Niacin in patients with Low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365, 2255-2267 (2011).
33. The Accord Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
34. Cannon, C., On behalf of the IMPROVE-IT study group. IMProved Reduction of OUtcomes: Vytorin Efficacy International Trial. Presented at the American Heart Association Scientific Sessions, November 17, 2014 (serial on the Internet).
35. Seidah, N.G., et al,. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. U. S. A. 100, 928-933 (2003).
36. Seidah, N.G., &, Prat, A., The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 11, 367-383 (2012).
37. Cunningham, D., et al,. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14, 413-419 (2007).
38. Abifadel, M., et al,. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34, 154-156 (2003).
39. Maxwell, K.N., &, Breslow, J.L., Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia. Curr. Opin. Lipidol. 16, 167-172 (2005).
40. Humphries, S.E., et al,. Mutational analysis in UK patients with a clinical diagnosis of familial hypercholesterolaemia: relationship with plasma lipid traits, heart disease risk and utility in relative tracing. J. Mol. Med. (Berl) 84, 203-214 (2006).
41. Allard, D., et al,. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia. Hum. Mutat. 26, 497-498 (2005).
42. Fasano, T., et al,. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol. Arterioscler. Thromb. Vasc. Biol. 27, 677-681 (2007).
43. Zhao, Z., et al,. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514-523 (2006).
44. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M., &, Burnett, J.R., The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193, 445-448 (2007).
45. Cohen, J., et al,. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37, 161-165 (2005).
46. Cohen, J.C., Boerwinkle, E., Mosley, T.H. Jr., &, Hobbs, H.H., Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354, 1264-1272 (2006).
47. Benn, M., Nordestgaard, B.G., Grande, P., Schnohr, P., &, Tybjaerg-Hansen, A., PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. J. Am. Coll. Cardiol. 55, 2833-2842 (2010).
48. Hooper, A.J., Marais, A.D., Tanyanyiwa, D.M., &, Burnett, J.R., The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193, 445-448 (2007).
49. Zhao, Z., et al,. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79, 514-523 (2006).
50. Zhang, D.W., et al,. Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J. Biol. Chem. 282, 18602-18612 (2007).
51. Poirier, S., et al,. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 283, 2363-2372 (2008).
52. Schmidt, R.J., et al,. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo. Biochem. Biophys. Res. Commun. 370, 634-640 (2008).
53. Le May, C., et al,. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 29, 684-690 (2009).
54. Denis, M., et al,. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation 125: 894-901 (2012).
55. Tang, Z., et al,. PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages. Int. J. Mol. Med. 30, 931-938 (2012).
56. Kysenius, K., Muggalla, P., Mätlik, K., Arumaë, U., &, Huttunen, H.J., PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell. Mol. Life Sci. 69, 1903-1916 (2012).
57. Sharotri, V., Collier, D.M., Olson, D.R., Zhou, R., &, Snyder, P.M., Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9). J. Biol. Chem. 287, 19266-19274 (2012).
58. Mbikay, M., et al,. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 584, 701-706 (2010).
59. Roubtsova, A., et al,. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler. Thromb. Vasc. Biol. 31, 785-791 (2011).
60. Tavori, H., Rashid, S., &, Fazio, S., On the function and homeostasis of PCSK9: teciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 238, 264-270 (2014).
61. Awan, Z., et al,. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin. Chem. 58, 183-189 (2012).
62. Urban, D., Pöss, J., Böhm, M., &, Laufs, U., Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis. J. Am. Coll. Cardiol. 62, 1401-1408 (2013).
63. Graham, M.J., et al,. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48, 763-767 (2007).
64. Frank-Kamenetsky, M., et al,. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. U. S.A. 105, 11915-11920 (2008).
65. Mitchell, T., et al,. Pharmacologic profile of the Adnectin BMS-962476, a small protein biologic alternative to PCSK9 antibodies for low-density lipoprotein lowering. J. Pharmacol. Exp. Ther. 350, 412-424 (2014).
66. Zhang, Y., et al,. Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptor. J. Biol. Chem. 289, 942-955 (2014).
67. Shimada, Y.J., &, Cannon, C.P., PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur. Heart J. 36, 2415-1424 (2015).
68. Chan, J.C., et al,. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 106, 9820-9825 (2009).
69. Dias, C.S., et al,. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J. Am. Coll. Cardiol. 60, 1888-1898 (2012).
70. Sullivan, D., et al,. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 308, 2497-2506 (2012).
71. Raal, F., et al,. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 126, 2408-2417 (2012).
72. Koren, M.J., et al,. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 380, 1995-2006 (2012).
73. Roth, E.M., et al,. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized phase 3 trial. Int. J. Cardiol. 176, 55-61 (2014).
74. Joseph, L., &, Robinson, J.G., Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog. Cardiovasc. Dis. 58, 19-31 (2015).
75. Koren, M.J., et al,. MENDEL-2 Investigators. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J. Am. Coll. Cardiol. 63, 2531-2540 (2014).
76. Blom, D.J., et al,. DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 370, 1809-1819 (2014).
77. Kereiakes, J.G.R., et al,. Efficacy and safety of alirocumab in high cardiovascular risk patients with suboptimally controlled hypercholesterolemia on maximally tolerated doses of statins: the ODYSSEY COMBO I study under late-breaking clinical trial abstracts. Circulation 130, 2105-2126 (2014).
78. Cannon, C.B., et al,. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study. Late-breaking clinical trial presented at the European Society of Cardiology Congress, Barcelona, Spain. 2014.
79. Harold Bays, M.F., et al,. Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II under late-breaking clinical trial abstracts. Circulation 130 (2014).
80. Robinson, J.G., et al,. ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1489-1499 (2015).
81. Robinson, J.G., et al,. Effect of evolocumab or ezetimibe added to moderate-or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA 311, 1870-1882 (2014).
82. Stroes, E., et al,. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. J. Am. Coll. Cardiol. 63, 2541-2548 (2014).
83. Patrick, M., et al,. ODYSSEY ALTERNATIVE: efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as defined by a placebo run-in and statin rechallenge arm under late-breaking clinical trial abstracts. Circulation 130, 2108 (2014).
84. Kastelein, J.J.P., et al,. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia (heFH) not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies. Late-breaking clinical trial presented at the European Society of Cardiology Congress, Barcelona, Spain. 2014.
85. Ginsberg, D.J.R., et al,. ODYSSEY HIGH FH: efficacy and safety of alirocumab in patients with severe heterozygous familial hypercholesterolemia under late-breaking clinical trial abstracts. Circulation 130, 2119 (2014).
86. Raal, F.J., et al,. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 385, 331-340 (2014).
87. Raal, F.J., et al,. TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet. 385, 341-350 (2014).
88. Sabatine, M.S., et al,. Open-label study of long-term evaluation against LDL cholesterol (OSLER) investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372, 1500-1509.
89. Navarese, E.P., et al,. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann. Intern. Med. 163, 40-51 (2015).
90. Sanofi/Regeneron. ODYSSEY outcomes: evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab SAR236553 (REGN727). ClinicalTrials.gov Identifier: NCT01663402. 2015.
91. Amgen. Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER). ClinicalTrials.gov Identifier: NCT01764633. 2014.
92. Pfizer. The evaluation of bococizumab (PF-04950615;RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-1). ClinicalTrials.gov Identifier: NCT01975376. 2015.
93. Pfizer. The evaluation of bococizumab (PF-04950615; RN316) in reducing the occurrence of major cardiovascular events in high risk subjects (SPIRE-2). ClinicalTrials.gov Identifier: NCT01975389. 2015.
94. Amgen. Global assessment of plaque regression with a PCSK9 antibody as measured by intra-vascular ultrasound (GLAGOV) NCT01813422. 2015.
95. Praluent (alirocumab injection) [prescribing information]. Sanofi Aventis, Regeneron Pharmaceuticals, 2015. < http://products.sanofi.us/praluent/praluent.pdf >
96. Sanofi Aventis, Regeneron Pharmaceuticals. Press release, 24 July 2015.
97. Puri, R., et al,. Impact of baseline lipoprotein and c-reactive protein levels on coronary atheroma regression following high-intensity statin therapy. Am. J. Cardiol 114, 1465-1472 (2014).
98. Heart Protection Study Collaborative G. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet 378, 2013-2020 (2011).
99. Robinson, J.G., &, Gidding, S.S., Curing atherosclerosis should be the next major cardiovascular prevention goal. J. Am. Coll. Cardiol. 63, 2779-2785 (2014).
100. Giugliano, R.P., &, Sabatine, M.S., Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J. Am. Coll. Cardiol. 65, 2638-2651 (2015).